Physician profile
Jack Barbour
NPI 1568482792
$870.23
in general payments reported to CMS, 2019-2025
12 companies · $52.96 in 2025
The $52.96 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.31 · 2020: $38.48 · 2021: $207 · 2022: $247 · 2023: $278 · 2024: $33.51 · 2025: $52.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $196.11 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $168.93 | 2021-2023 | Aristada, Vivitrol, Lybalvi |
| Neurocrine Biosciences, INC. | $125.68 | 2021-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.34 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $65.87 | 2020-2025 | Abilify Asimtufii |
| Indivior INC. | $61.48 | 2020-2022 | |
| Harmony Biosciences LLC | $37.33 | 2023 | Wakix |
| Teva Pharmaceuticals USA, INC. | $33.98 | 2023 | Uzedy |
| Vanda Pharmaceuticals INC. | $33.51 | 2024 | Hetlioz, Fanapt |
| Abbvie INC. | $26.06 | 2021 | |
| Lundbeck LLC | $14.63 | 2021 | |
| Hologic Sales and Service, LLC | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Barbour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.